Logo image of ALINS.PA

INTRASENSE SAS (ALINS.PA) Stock Fundamental Analysis

EPA:ALINS - Euronext Paris - Matif - FR0011179886 - Common Stock - Currency: EUR

0.27  +0.01 (+5.47%)

Fundamental Rating

3

Taking everything into account, ALINS scores 3 out of 10 in our fundamental rating. ALINS was compared to 12 industry peers in the Health Care Technology industry. ALINS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, ALINS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ALINS has reported negative net income.
ALINS had a negative operating cash flow in the past year.
In the past 5 years ALINS always reported negative net income.
In the past 5 years ALINS reported 4 times negative operating cash flow.
ALINS.PA Yearly Net Income VS EBIT VS OCF VS FCFALINS.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1M -2M -3M -4M

1.2 Ratios

With a Return On Assets value of -34.24%, ALINS is not doing good in the industry: 81.82% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -49.10%, ALINS is doing worse than 81.82% of the companies in the same industry.
Industry RankSector Rank
ROA -34.24%
ROE -49.1%
ROIC N/A
ROA(3y)-33.5%
ROA(5y)-26.65%
ROE(3y)-81.07%
ROE(5y)-87.01%
ROIC(3y)N/A
ROIC(5y)N/A
ALINS.PA Yearly ROA, ROE, ROICALINS.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

The Gross Margin of ALINS (89.08%) is better than 81.82% of its industry peers.
In the last couple of years the Gross Margin of ALINS has grown nicely.
ALINS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 89.08%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y3.44%
ALINS.PA Yearly Profit, Operating, Gross MarginsALINS.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50 -100

More info and screens

6

2. Health

2.1 Basic Checks

ALINS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALINS has more shares outstanding
ALINS has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ALINS has an improved debt to assets ratio.
ALINS.PA Yearly Shares OutstandingALINS.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
ALINS.PA Yearly Total Debt VS Total AssetsALINS.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

2.2 Solvency

An Altman-Z score of 3.04 indicates that ALINS is not in any danger for bankruptcy at the moment.
ALINS has a Altman-Z score of 3.04. This is in the better half of the industry: ALINS outperforms 63.64% of its industry peers.
ALINS has a Debt/Equity ratio of 0.16. This is a healthy value indicating a solid balance between debt and equity.
ALINS has a Debt to Equity ratio of 0.16. This is in the better half of the industry: ALINS outperforms 63.64% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Altman-Z 3.04
ROIC/WACCN/A
WACC7.21%
ALINS.PA Yearly LT Debt VS Equity VS FCFALINS.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2M -2M 4M -4M 6M

2.3 Liquidity

ALINS has a Current Ratio of 3.45. This indicates that ALINS is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ALINS (3.45) is better than 81.82% of its industry peers.
A Quick Ratio of 3.45 indicates that ALINS has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.45, ALINS belongs to the top of the industry, outperforming 81.82% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.45
Quick Ratio 3.45
ALINS.PA Yearly Current Assets VS Current LiabilitesALINS.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 6.75% over the past year.
The Revenue for ALINS has decreased by -42.65% in the past year. This is quite bad
The Revenue has been growing slightly by 1.53% on average over the past years.
EPS 1Y (TTM)6.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.22%
Revenue 1Y (TTM)-42.65%
Revenue growth 3Y-1.34%
Revenue growth 5Y1.53%
Sales Q2Q%-44.77%

3.2 Future

ALINS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.57% yearly.
The Revenue is expected to grow by 16.54% on average over the next years. This is quite good.
EPS Next Y0%
EPS Next 2Y17.26%
EPS Next 3Y17.57%
EPS Next 5YN/A
Revenue Next Year-29.35%
Revenue Next 2Y10.07%
Revenue Next 3Y16.54%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ALINS.PA Yearly Revenue VS EstimatesALINS.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2B 4B 6B
ALINS.PA Yearly EPS VS EstimatesALINS.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ALINS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ALINS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALINS.PA Price Earnings VS Forward Price EarningsALINS.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALINS.PA Per share dataALINS.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 -0.05 0.1

4.3 Compensation for Growth

A more expensive valuation may be justified as ALINS's earnings are expected to grow with 17.57% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.26%
EPS Next 3Y17.57%

More info and screens

0

5. Dividend

5.1 Amount

ALINS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INTRASENSE SAS

EPA:ALINS (2/4/2025, 7:00:00 PM)

0.27

+0.01 (+5.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)09-25 2024-09-25
Earnings (Next)02-06 2025-02-06
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap14.21M
Analysts40
Price Target0.24 (-11.11%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.3
P/FCF N/A
P/OCF N/A
P/B 1.95
P/tB 3.56
EV/EBITDA N/A
EPS(TTM)-0.08
EYN/A
EPS(NY)-0.05
Fwd EYN/A
FCF(TTM)-0.09
FCFYN/A
OCF(TTM)-0.06
OCFYN/A
SpS0.06
BVpS0.14
TBVpS0.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -34.24%
ROE -49.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 89.08%
FCFM N/A
ROA(3y)-33.5%
ROA(5y)-26.65%
ROE(3y)-81.07%
ROE(5y)-87.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y3.44%
F-Score4
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 273.97%
Cap/Sales 58.28%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.45
Quick Ratio 3.45
Altman-Z 3.04
F-Score4
WACC7.21%
ROIC/WACCN/A
Cap/Depr(3y)159.67%
Cap/Depr(5y)249.68%
Cap/Sales(3y)36.91%
Cap/Sales(5y)29.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.22%
EPS Next Y0%
EPS Next 2Y17.26%
EPS Next 3Y17.57%
EPS Next 5YN/A
Revenue 1Y (TTM)-42.65%
Revenue growth 3Y-1.34%
Revenue growth 5Y1.53%
Sales Q2Q%-44.77%
Revenue Next Year-29.35%
Revenue Next 2Y10.07%
Revenue Next 3Y16.54%
Revenue Next 5YN/A
EBIT growth 1Y-4.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-49.54%
EBIT Next 3Y8.56%
EBIT Next 5YN/A
FCF growth 1Y-44.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-55.48%
OCF growth 3YN/A
OCF growth 5YN/A